Insider Selling: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Sells $100,149.00 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) major shareholder Barry Canton sold 75,300 shares of the business’s stock in a transaction dated Tuesday, March 14th. The stock was sold at an average price of $1.33, for a total transaction of $100,149.00. Following the sale, the insider now directly owns 13,918,194 shares in the company, valued at approximately $18,511,198.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Barry Canton also recently made the following trade(s):

• On Wednesday, February 8th, Barry Canton sold 128,864 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.88, for a total transaction of $242,264.32.
• On Tuesday, January 31st, Barry Canton sold 149,554 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.85, for a total transaction of $276,674.90.
• On Friday, January 27th, Barry Canton sold 145,907 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.82, for a total transaction of $265,550.74.
• On Wednesday, January 25th, Barry Canton sold 158,748 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.73, for a total transaction of $274,634.04.
• On Monday, January 23rd, Barry Canton sold 143,808 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.75, for a total transaction of $251,664.00.
• On Thursday, January 19th, Barry Canton sold 199,843 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.71, for a total transaction of $341,731.53.
• On Tuesday, January 17th, Barry Canton sold 151,530 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.86, for a total transaction of $281,845.80.
• On Thursday, January 12th, Barry Canton sold 190,343 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.70, for a total transaction of $323,583.10.
• On Tuesday, January 10th, Barry Canton sold 157,798 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.50, for a total transaction of $236,697.00.
• On Wednesday, January 4th, Barry Canton sold 37,650 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $1.56, for a total transaction of $58,734.00.

Ginkgo Bioworks Stock Down 3.0 %

Shares of DNA stock opened at $1.28 on Friday. Ginkgo Bioworks Holdings, Inc. has a one year low of $1.19 and a one year high of $4.91. The company has a 50 day moving average price of $1.66 and a 200 day moving average price of $2.14.

Hedge Funds Weigh In On Ginkgo Bioworks

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. increased its position in Ginkgo Bioworks by 19.6% during the fourth quarter. Baillie Gifford & Co. now owns 244,176,643 shares of the company’s stock worth $412,659,000 after purchasing an additional 40,099,800 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Ginkgo Bioworks by 13.9% in the fourth quarter. ARK Investment Management LLC now owns 144,384,067 shares of the company’s stock worth $244,009,000 after acquiring an additional 17,565,211 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Ginkgo Bioworks by 21.1% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 37,514,318 shares of the company’s stock worth $63,399,000 after acquiring an additional 6,532,370 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Ginkgo Bioworks by 21.1% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 37,514,318 shares of the company’s stock worth $63,399,000 after acquiring an additional 6,532,370 shares in the last quarter. Finally, State Street Corp increased its position in shares of Ginkgo Bioworks by 6.3% in the third quarter. State Street Corp now owns 13,190,686 shares of the company’s stock worth $41,155,000 after acquiring an additional 778,831 shares in the last quarter. Institutional investors and hedge funds own 61.83% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DNA. Raymond James cut their price objective on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Friday, March 3rd. Berenberg Bank began coverage on shares of Ginkgo Bioworks in a research report on Monday, November 28th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, BTIG Research cut their price objective on shares of Ginkgo Bioworks from $4.00 to $3.00 in a research report on Sunday, March 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and a consensus price target of $4.39.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.